Truist Financial Corp Crispr Therapeutics Ag Transaction History

Truist Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 26, 2022	BUY	$61.1 - $83.78 $164,908 - $226,122	2,699 Added 81.86%	5,996 $392,000
Q2 2022 Jul 22, 2022	SELL	$43.23 - $73.83 $17,119 - $29,236	-396 Reduced 10.72%	3,297 $200,000
Q1 2022 Apr 22, 2022	SELL	$53.19 - $79.24 $22,499 - $33,518	-423 Reduced 10.28%	3,693 $232,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $278,818 - $442,711	-3,978 Reduced 49.15%	4,116 $312,000
Q3 2021 Nov 05, 2021	BUY	$110.2 - $156.64 $156,043 - $221,802	1,416 Added 21.2%	8,094 $906,000
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $48,201 - $77,383	-478 Reduced 6.68%	6,678 $1.08 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $38,198 - $72,463	345 Added 5.07%	7,156 $872,000
Q4 2020 Feb 18, 2021	BUY	$79.67 - $173.23 $236,779 - $514,839	2,972 Added 77.42%	6,811 $1.04 Million
Q3 2020 Nov 13, 2020	SELL	$78.5 - $100.64 $49,769 - $63,805	-634 Reduced 14.17%	3,839 $321,000
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $42,812 - $84,567	-1,112 Reduced 19.91%	4,473 $329,000
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $188,102 - $349,230	5,585 New	5,585 $236,000

489

57.9M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.1B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.